Previous close | 35.00 |
Open | 34.67 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 34.67 - 34.67 |
52-week range | 25.75 - 35.52 |
Volume | |
Avg. volume | 18,196 |
Market cap | 15.058B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 192.61 |
EPS (TTM) | 0.18 |
Earnings date | N/A |
Forward dividend & yield | 0.50 (1.43%) |
Ex-dividend date | 03 May 2024 |
1y target est | N/A |
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the f
All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board membersDividend of CHF 0.45 per registered dividend-paying share approved, representing 24% of core net income Basel, April 30, 2024 – Sandoz (SIX: SDZ; OTCQX: SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its